• Participant has histologically or cytologically confirmed metastatic NSCLC (stage IV with known subtype).

• Participant has progressed radiographically on or after receiving:

‣ One prior line of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy concomitantly) in the metastatic disease setting; OR

⁃ No more than 2 prior lines of therapy (PD-1/PD-L1 inhibitor and platinum-based chemotherapy sequentially, irrespective of the order) in the metastatic disease setting.

• Participant must have positive tumor PD-L1 expression (tumor cells ≥1%) determined prospectively on a tumor sample from the metastatic setting at a sponsor-designated central laboratory.

• Participant has measurable disease according to RECIST v1.1 as assessed by the investigator at baseline.

• Participant has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 within 7 days of Cycle 1 Day 1.

• Participant has a life expectancy of ≥3 months.

• Participant must have adequate organ and bone marrow function, per laboratory test results within 7 days of trial treatment.